Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2022-04-07 Director's Dealing
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
111年03月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings of company insiders, including directors, managers, and their related parties. It shows the number of shares held, changes in holdings, and classifications of shares. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of a full financial report, earnings release, or meeting materials. The document is not a proxy statement or voting results announcement. It is a report of personal share transactions and holdings by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is over 11,000 characters, indicating it is a substantive report, not a brief announcement or certification. Therefore, the appropriate classification is DIRS with high confidence.
2022-04-07 Chinese
111年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors and senior management, showing their current holdings, pledged shares, and related party holdings. It is a disclosure of insider shareholdings and pledges, typical of a Director's Dealing or insider shareholding notification. There is no indication of financial results, meeting materials, or report announcements. The document is relatively short (2471 characters) and focuses solely on insider shareholdings. Therefore, the best fitting category is Director's Dealing (DIRS).
2022-04-07 Chinese
111年3月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 科妍, reporting on the status of fund loans and endorsement guarantees for the current and previous month, with zero balances and no guarantees. It contains no detailed financial statements, no management discussion, no voting results, no legal or regulatory announcements, and no mention of any report publication or certification. The content is a routine regulatory disclosure of financial guarantees and loans, typical of a general regulatory announcement. The document length is very short (601 characters), and it does not indicate it is an announcement of a report or a full report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2022-04-06 Chinese
111年3月營業收入
Fund Information / Factsheet Classification · 95% confidence The document is a brief financial summary report showing monthly and cumulative net operating revenue figures for a company named 科妍 for the period of 民國111年03月 (March 2022). It includes percentage changes compared to the previous year and explanatory notes about accounting standards and reporting practices. The document length is very short (765 characters) and contains only summarized financial data without detailed financial statements or analysis. It does not represent a full annual or interim report, nor is it an announcement of a report publication. The content fits the description of a Fund Information / Factsheet (FS), which is a brief summary of key company financials and market info.
2022-04-06 Chinese
110年第4季海外子公司投資
Interim / Quarterly Report Classification · 85% confidence The document contains financial data related to investment in overseas subsidiaries, including shareholding percentages, original investment amounts, investment balances, and recognized investment gains or losses for a specific quarter (110年4季, which corresponds to Q4 of the 110th year in the Taiwanese calendar). The content is tabular and provides detailed financial figures rather than just an announcement or summary. The document length is short (664 characters), but it contains substantive financial data, not just a notice or certification. This matches the characteristics of an Interim / Quarterly Report (IR), which includes comprehensive financial data for a period shorter than a full fiscal year. There is no indication that this is an announcement of a report or a certification, so it should not be classified as RPA or RNS. Therefore, the best fit is IR (Interim / Quarterly Report). FY 2021
2022-03-23 Chinese
110年第4季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment amounts, investment methods, and related financial figures concerning investments in mainland China by a Taiwanese listed company. It includes specific financial data such as capital amounts, investment gains/losses, and regulatory approval limits. The document is relatively short (1289 characters) and focuses on investment disclosures rather than a full financial report or announcement. It does not contain comprehensive financial statements or management discussion, nor is it an announcement of a report publication. The content aligns with regulatory filings related to investment disclosures required by authorities but does not fit into other specific categories like Annual Report, Interim Report, or Capital/Financing Update. Therefore, the best classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory disclosures that do not fit other categories.
2022-03-23 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.